Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
This article was originally published in The Pink Sheet Daily
Executive Summary
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.
You may also be interested in...
Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28
Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.
Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.